For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Vyndamax and the formulated version represents a genuine change. These novel therapies protect the transthyretin protein, slowing its harmful build-up and reducing the impact of the disease . People are now seeing improvements in their qu… Read More